175 related articles for article (PubMed ID: 20724078)
21. Update on endocrine therapy for breast cancer.
Buzdar AU; Hortobagyi G
Clin Cancer Res; 1998 Mar; 4(3):527-34. PubMed ID: 9533518
[TBL] [Abstract][Full Text] [Related]
22. [LH-RH analogue for the treatment in premenopausal, receptor-positive breast cancer].
Sano M; Makino H
Nihon Rinsho; 2000 Apr; 58 Suppl():328-33. PubMed ID: 11026014
[No Abstract] [Full Text] [Related]
23. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
Rossi E; Morabito A; De Maio E; Di Rella F; Esposito G; Gravina A; Labonia V; Landi G; Nuzzo F; Pacilio C; Piccirillo MC; D'Aiuto G; D'Aiuto M; Rinaldo M; Botti G; Gallo C; Perrone F; de Matteis A
J Clin Oncol; 2008 Jan; 26(2):264-70. PubMed ID: 18086795
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
Ortmann O; Cufer T; Dixon JM; Maass N; Marchetti P; Pagani O; Pronzato P; Semiglazov V; Spano JP; Vrdoljak E; Wildiers H
Breast; 2009 Feb; 18(1):2-7. PubMed ID: 19036588
[TBL] [Abstract][Full Text] [Related]
25. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):516-25. PubMed ID: 17405996
[TBL] [Abstract][Full Text] [Related]
26. Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer.
Briest S; Wolff AC
Expert Rev Anticancer Ther; 2007 Sep; 7(9):1243-53. PubMed ID: 17892424
[TBL] [Abstract][Full Text] [Related]
27. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?
Prowell TM; Davidson NE
Oncologist; 2004; 9(5):507-17. PubMed ID: 15477635
[TBL] [Abstract][Full Text] [Related]
28. [Postoperative adjuvant therapy for premenopausal patients with breast cancer].
Kurebayashi J
Nihon Rinsho; 2006 Oct; 64(10):1963-9. PubMed ID: 17037375
[TBL] [Abstract][Full Text] [Related]
29. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
[TBL] [Abstract][Full Text] [Related]
30. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
Parton M; Smith IE
J Clin Oncol; 2008 Feb; 26(5):745-52. PubMed ID: 18258982
[No Abstract] [Full Text] [Related]
31. Endocrine management of breast cancer.
Schneider PG; Jackisch C; Brandt B
Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():115-27. PubMed ID: 7874188
[TBL] [Abstract][Full Text] [Related]
32. Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women.
Jonat W
Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):1-5. PubMed ID: 11900209
[TBL] [Abstract][Full Text] [Related]
33. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer.
Iwase H
Breast Cancer; 2008; 15(4):278-90. PubMed ID: 18810576
[TBL] [Abstract][Full Text] [Related]
34. [Developments in endocrine therapy for breast cancer].
Matsui A; Ikeda T; Jinno H; Tajima G; Hohjou T; Tokura H; Mitsui Y; Asaga S; Muto T; Kitajima M
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1138-45. PubMed ID: 12145993
[TBL] [Abstract][Full Text] [Related]
35. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
Poole R; Paridaens R
Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
[TBL] [Abstract][Full Text] [Related]
36. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
Ward JH
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
[TBL] [Abstract][Full Text] [Related]
37. Luteinizing hormone-releasing hormone (LHRH) agonists in the treatment of breast cancer.
Hackshaw A
Expert Opin Pharmacother; 2009 Nov; 10(16):2633-9. PubMed ID: 19874248
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer adjuvant endocrine therapy.
Cigler T; Goss PE
Cancer J; 2007; 13(3):148-55. PubMed ID: 17620763
[TBL] [Abstract][Full Text] [Related]
39. Hormonal approaches to breast cancer treatment and prevention: an overview.
Vogel CL
Semin Oncol; 1996 Aug; 23(4 Suppl 9):2-9. PubMed ID: 8824459
[TBL] [Abstract][Full Text] [Related]
40. The Role of Ovarian Suppression in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer.
Jain S; Santa-Maria CA; Gradishar WJ
Oncology (Williston Park); 2015 Jul; 29(7):473-8, 481. PubMed ID: 26178334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
